Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

Stock Information for Zealand Pharma A/S

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zealand Pharma A/S

Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
REMINDER: Zealand Pharma's Capital Markets Day on December 11, 2025
Zealand Pharma Announces Financial Results for the First Nine Months of 2025
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.